Koers Midatech Pharma PLC Nasdaq
Aandelen
US59564R1041
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 26K 32,88K 30,61K | Omzet 2025 * | 13K 16,44K 15,31K | Marktkapitalisatie | 6,83 mln. 8,64 mln. 8,04 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | 263 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 525 x |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 0,09% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Stamp
CEO | Chief Executive Officer | 62 | 09-09-19 |
Dan Palmer
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | 44 | 11-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Parker
CHM | Chairman | 65 | 20-06-22 |
Sijmen de Vries
BRD | Director/Board Member | 65 | 13-11-14 |
Stephen Stamp
CEO | Chief Executive Officer | 62 | 09-09-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,82% | 121 mld. | |
+20,35% | 113 mld. | |
+17,47% | 26,02 mld. | |
-25,31% | 19,39 mld. | |
-19,51% | 15,91 mld. | |
-19,67% | 15,09 mld. | |
-46,87% | 15,06 mld. | |
+62,55% | 14,93 mld. | |
+6,34% | 13,85 mld. |